initial public offerings (IPOs) trading on American exchanges

Wednesday, January 22, 2014

Acceleron Pharma (XLRN) began trading on the NASDAQ on 18 September 2013

Jan 2014 update


Acceleron Pharma Inc. is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of protein therapeutics for cancer and rare diseases. The Company’s research focuses on the biology of the Transforming Growth Factor-Beta (TGF-b) protein superfamily, a large and diverse group of molecules that are key regulators in the growth and repair of tissues throughout the human body. By coupling its discovery and development expertise, including its knowledge of the TGF-b superfamily, with its internal protein engineering and manufacturing capabilities, it has built a productive research and development platform that has generated clinical and preclinical protein therapeutic candidates with mechanisms of action.


128 Sidney Street
United States 

Key stats and ratios

Q3 (Sep '13)2012
Net profit margin-433.56%-213.60%
Operating margin-422.32%-204.17%
EBITD margin--13.39%
Return on average assets-88.78%-52.98%
Return on average equity--

No comments:

Post a Comment